
Mette SÃ, ndergaard Deleuran

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7465220/publications.pdf

Version: 2024-02-01



Mette SÃ, NDERGAARD

#	Article	IF	CITATIONS
1	Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. Journal of Dermatological Treatment, 2022, 33, 266-277.	2.2	17
2	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Journal of Dermatological Treatment, 2022, 33, 1608-1616.	2.2	14
3	Combined dapsone and sulfapyridine for the treatment of therapy-resistant linear IgA bullous dermatosis: Two case reports. JAAD Case Reports, 2022, 21, 119-122.	0.8	3
4	Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). Journal of the American Academy of Dermatology, 2022, 87, 351-358.	1.2	39
5	Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A Systematic Review of Best-Evidenced Treatment Options. Dermatology, 2022, 238, 950-960.	2.1	6
6	Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2022, 23, 393-408.	6.7	36
7	Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 948-957.	2.4	11
8	Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia. Pediatric Allergy and Immunology, 2021, 32, 331-341.	2.6	14
9	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Dermato-Venereologica, 2021, 101, adv00402.	1.3	45
10	Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use. Acta Dermato-Venereologica, 2021, 101, adv00504.	1.3	8
11	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVIDâ€19 (SARSâ€CoVâ€2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
12	Atopic dermatitis and psoriasis: so much more than "just skin diseasesâ€: Annales De Dermatologie Et De Venereologie, 2021, 148, 5.	1.0	0
13	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
14	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four PhaseÂ3 Trials. Dermatology and Therapy, 2021, 11, 1357-1372.	3.0	19
15	Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Manifesting as Lymphocytic Interstitial Pneumonia and Treatment-Resistant Bullous Pemphigoid. Pediatric, Allergy, Immunology, and Pulmonology, 2021, 34, 76-79.	0.8	2
16	Therapeutic education in atopic dermatitis: A position paper from the International Eczema Council. JAAD International, 2021, 3, 8-13.	2.2	8
17	Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort. International Journal of Women's Dermatology, 2021, 7, 708-715.	2.0	8
18	Appraisal of Proactive Topical Therapy in Atopic Dermatitis: Pros and Cons. American Journal of Clinical Dermatology, 2021, 22, 775-783.	6.7	8

Mette SÃ, NDERGAARD

#	Article	IF	CITATIONS
19	Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2143-2148.	2.4	5
20	Effective clinical study recruitment of patients with atopic dermatitis through social media. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e922-e923.	2.4	2
21	Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	2.5	43
22	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 2020, 82, 377-388.	1.2	155
23	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.5	14
24	The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. British Journal of Dermatology, 2020, 182, 1331-1342.	1.5	102
25	Realâ€world evidence vs. randomized control trials. British Journal of Dermatology, 2020, 182, 275-276.	1.5	0
26	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2717-2744.	2.4	220
27	How "benign―is cutaneous mastocytosis? A Danish registry-based matched cohort study. International Journal of Women's Dermatology, 2020, 6, 294-300.	2.0	4
28	Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e773-e776.	2.4	10
29	An Emollient Containing Aquaphilus dolomiae Extract is Effective in the Management of Xerosis and Pruritus: An International, Real-World Study. Dermatology and Therapy, 2020, 10, 1013-1029.	3.0	14
30	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2020, 21, 567-577.	6.7	78
31	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
32	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS ovâ€2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
33	Memory Buttons in Combination with Mobile Application-Induced Objective and Subjective Effects in Patients with Atopic Dermatitis. Dermatology Research and Practice, 2020, 2020, 1-6.	0.8	7
34	The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderateâ€ŧoâ€severe atopic eczema*. British Journal of Dermatology, 2020, 183, 1073-1082.	1.5	25
35	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema (<scp>TREAT</scp>) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo―and systemic therapy registries. British Journal of Dermatology, 2019, 180, 790-801.	1.5	26
36	Emerging Terbinafine Resistance in <i>Trichophyton</i> : Clinical Characteristics, Squalene Epoxidase Gene Mutations, and a Reliable EUCAST Method for Detection. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	109

Mette SÃ, Ndergaard

#	Article	IF	CITATIONS
37	Severe Infantile Bullous Pemphigoid Treated with Dapsone after Bridging with Systemic Glucocorticoid. Case Reports in Dermatology, 2019, 11, 187-193.	0.8	4
38	Editorial overview: Dermatology is moving forward. Current Opinion in Pharmacology, 2019, 46, vi-viii.	3.5	0
39	<scp>TRE</scp> atment of <scp>AT</scp> opic eczema (<scp>TREAT</scp>) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries. British Journal of Dermatology, 2019, 181, 492-504.	1.5	29
40	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
41	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology, 2019, 20, 443-456.	6.7	130
42	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1224-1231.	2.4	50
43	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science, 2019, 94, 266-275.	1.9	121
44	Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase <scp>III</scp> clinical trials. British Journal of Dermatology, 2019, 181, 196-197.	1.5	28
45	SAT0006â€T-CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3 (TIM-3) IS INCREASED IN ACTIVE RHEUMATOID ARTHRITIS AND ASSOCIATED WITH CLINICAL DISEASE ACTIVITY AND RADIOGRAPHIC PROGRESSION. , 2019, , .		0
46	Current pharmaceutical developments in atopic dermatitis. Current Opinion in Pharmacology, 2019, 46, 7-13.	3.5	26
47	Methotrexate in atopic eczema – Reply to a letter. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e155-e156.	2.4	0
48	Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 657-682.	2.4	727
49	Children with atopic dermatitis may have unacknowledged contact allergies contributing to their skin symptoms. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 428-436.	2.4	27
50	Consensusâ€based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: partÂll. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 850-878.	2.4	519
51	Contact allergy in Danish children: Current trends. Contact Dermatitis, 2018, 79, 295-302.	1.4	38
52	Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. British Journal of Dermatology, 2017, 176, 1486-1491.	1.5	56
53	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials, 2017, 18, 87.	1.6	21
54	Contact allergy in children with atopic dermatitis: a systematic review. British Journal of Dermatology, 2017, 177, 395-405.	1.5	57

Mette SÃ, Ndergaard

#	Article	IF	CITATIONS
55	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <scp>TOPICOP</scp> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	5.7	52
56	The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. Journal of Investigative Dermatology, 2017, 137, 2014-2016.	0.7	25
57	When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. Journal of the American Academy of Dermatology, 2017, 77, 623-633.	1.2	170
58	Increasing Comorbidities Suggest that Atopic DermatitisÂlsÂaÂSystemic Disorder. Journal of Investigative Dermatology, 2017, 137, 18-25.	0.7	283
59	Allergic Contact Dermatitis Caused by Pâ€Tertâ€Butylphenolâ€Formaldehyde Resin in Orthopedic Braces. Pediatric Dermatology, 2016, 33, e204-e205.	0.9	5
60	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 729-747.	2.4	329
61	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 2016, 375, 2335-2348.	27.0	1,467
62	Description and characterization of a penicillin-resistant <i>Streptococcus dysgalactiae</i> subsp <i>. equisimilis</i> clone isolated from blood in three epidemiologically linked patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3376-3380.	3.0	30
63	Photosensitivity in atopic dermatitis complicated by contact allergy to common sunscreen ingredients. Contact Dermatitis, 2016, 74, 56-58.	1.4	8
64	Attention-Deficit/Hyperactivity Disorder in Atopic Dermatitis: An Appraisal of the Current Literature. Pediatric, Allergy, Immunology, and Pulmonology, 2016, 29, 181-188.	0.8	13
65	Measuring serum concentrations of interleukin-33 in atopic dermatitis is associated with potential false positive results. SpringerPlus, 2016, 5, 33.	1.2	11
66	<scp>TSLP</scp> , <scp> IL</scp> â€31, <scp>IL</scp> â€33 and <scp>sST</scp> 2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1930-1938.	2.4	125
67	Global Allergy Forum and 3rd Davos Declaration 2015. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 588-592.	5.7	47
68	Characterization and scoring of skin changes in severe acute malnutrition in children between 6 months and 5 years of age. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2463-2469.	2.4	18
69	Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Therapeutic Advances in Chronic Disease, 2015, 6, 304-313.	2.5	33
70	Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology, 2015, 26, 306-315.	2.6	71
71	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. American Journal of Medicine, 2015, 128, 1325-1334.e2.	1.5	94
72	A Case Series Study of Eighty-Five Chronic Spontaneous Urticaria Patients Referred to a Tertiary Care Center. Annals of Dermatology, 2014, 26, 73.	0.9	13

Mette SÃ, Ndergaard

#	Article	IF	CITATIONS
73	Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities. Frontiers in Medicine, 2014, 1, 33.	2.6	18
74	Topical Calcineurin Inhibitors, Topical Glucocorticoids and Cancer in Children: A Nationwide Study. Acta Dermato-Venereologica, 2014, 96, 834-5.	1.3	3
75	Clinical heterogeneity and differential diagnosis of atopic dermatitis. British Journal of Dermatology, 2014, 170, 2-6.	1.5	44
76	Systemic Treatment of Severe Atopic Dermatitis in Children and Adults. Current Treatment Options in Allergy, 2014, 1, 384-396.	2.2	6
77	Methylprednisolone Therapy in Acute Hemorrhagic Edema of Infancy. Case Reports in Dermatological Medicine, 2014, 2014, 1-3.	0.3	7
78	Orofacial granulomatosis in children can be the initial manifestation of systemic disease: a presentation of two cases. Dermatology Reports, 2014, 6, 5039.	0.8	8
79	The European treatment of severe atopic eczema in children taskforce (TREAT) survey. British Journal of Dermatology, 2013, 169, 901-909.	1.5	94
80	Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1176-1193.	2.4	316
81	Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1114-1121.	5.7	201
82	Short Communications. Contact Dermatitis, 2000, 43, 169-185.	1.4	15
83	Purified Der p1 and p2 Patch Tests in Patients with Atopic Dermatitis: Evidence for Both Allergenicity and Proteolytic Irritancy: Investigative Reports. Acta Dermato-Venereologica, 1998, 78, 241-243.	1.3	46